Creotech Instruments (CRI) Q4 2024 earnings summary

Executive summary

• Revenue from product sales in 2024 was 25.7m PLN, down 5.0m PLN year-over-year, mainly due to the end of a major ESA project and reduced grant funding as several projects concluded their research phases.

• Operating costs increased, especially in wages, reflecting higher employment in production, R&D, and support functions.

• Net loss for 2024 was 20.5m PLN, compared to a net loss of 14.3m PLN in 2023.

• The company is actively investing in R&D and has initiated significant new contracts and projects post-year-end.

Financial highlights

• Operating revenue: 35.6m PLN in 2024 vs. 44.0m PLN in 2023.

• Product sales: 25.7m PLN (2024), 30.7m PLN (2023); grants: 9.9m PLN (2024), 13.3m PLN (2023).

• Operating loss: -24.8m PLN (2024), -16.9m PLN (2023).

• Net loss: -20.5m PLN (2024), -14.3m PLN (2023).

• Cash at year-end: 32.4m PLN (2024), 73.2m PLN (2023).

• Capital expenditures: 20.6m PLN in 2024, mainly for development work.

Outlook and guidance

• The company is raising capital through a new share issue to finance a major satellite contract and expects further funding from contract advances and potential debt.

• Plans to spin off the quantum systems segment into a separate listed entity to enhance focus and access to funding.